Movement Alert|UiPath Rises 10.31% in After-Hours Trading, Q2 Revenue Beats Expectations as UBS Raises Target Price to $19

Market Focus
Sep 04

On September 4, UiPath rose 10.31% in after-hours trading, trading at approximately $20.04 per share, with turnover of $21.76 million. The rally was driven by better-than-expected second fiscal quarter results released after the close, combined with a significant price target upgrade from UBS.

UiPath reported Q2 adjusted earnings per share of $0.15, in line with analyst consensus, while quarterly revenue came in at $410.26 million, comfortably beating the Street estimate of $397.95 million. The top-line beat extended the company's streak of double-digit revenue growth, following Q1 sales of $418.38 million which also exceeded expectations. Gross margin in the prior quarter stood at 81.63%, underscoring the strength of its subscription-driven business model.

Ahead of the report, UBS had raised its price target on UiPath from $12 to $19, maintaining a neutral rating, reflecting growing institutional confidence in the company's AI-driven business momentum. The company has been actively expanding its agentic AI capabilities, including collaborations with Deloitte for AI-led software testing and the launch of its document processing tool on Google Cloud Marketplace powered by Gemini.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10